Literature DB >> 12547149

Allelic imbalance in selected chromosomal regions in ovarian cancer.

Lise Lotte Hansen1, Lise Lind Jensen, Constantine Dimitrakakis, Stylianos Michalas, Fred Gilbert, Hugh R K Barber, Jens Overgaard, Iordanis I Arzimanoglou.   

Abstract

Ovarian cancer (OC) is often asymptomatic at the initial stage. When diagnosed, up to 75% of the patients present grade III or IV tumors with metastasis in nearby organs of the abdomen. Genetic imbalance is abundant in OC, and allelic loss (AL) of specific chromosomal regions is considered an early event. To establish association between genetic markers for early diagnosis/prognosis of OC, our target was to define narrow specific regions of AL. We analyzed 65 ovarian carcinomas by using 19 microsatellite markers located in three different chromosomes. First, a 7.6-Mb region containing the estrogen receptor (ESR1) and the tumor suppressor gene LATS1 was analyzed. Several chromosomal breakpoints flanking ESR1 affecting the region harboring LATS1 were found. Second, we found chromosomal breakpoints on 13q13.1 approximately q13.3 that defined two narrow regions flanking the BRCA2 locus. Third, our ovarian tumors exhibited a very high frequency of AL on 16q and chromosomal breakpoints defining two narrow regions within 16q22.2 approximately q24.3. In this article, we report three new polymorphic microsatellite markers and strong evidence of AL of narrow well-defined regions in hot spots on 6q, 13q, and 16q in ovarian tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12547149     DOI: 10.1016/s0165-4608(02)00620-9

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  9 in total

1.  New genetic variants of LATS1 detected in urinary bladder and colon cancer.

Authors:  Mona K Saadeldin; Heba Shawer; Ahmed Mostafa; Neemat M Kassem; Asma Amleh; Rania Siam
Journal:  Front Genet       Date:  2015-01-13       Impact factor: 4.599

2.  BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma.

Authors:  Christopher S Williams; Baolin Zhang; J Joshua Smith; Ashwath Jayagopal; Caitlyn W Barrett; Christopher Pino; Patricia Russ; Sai H Presley; DunFa Peng; Daniel O Rosenblatt; Frederick R Haselton; Jin-Long Yang; M Kay Washington; Xi Chen; Steven Eschrich; Timothy J Yeatman; Wael El-Rifai; R Daniel Beauchamp; Min S Chang
Journal:  J Clin Invest       Date:  2011-09-12       Impact factor: 14.808

3.  A major lung cancer susceptibility locus maps to chromosome 6q23-25.

Authors:  J E Bailey-Wilson; C I Amos; S M Pinney; G M Petersen; M de Andrade; J S Wiest; P Fain; A G Schwartz; M You; W Franklin; C Klein; A Gazdar; H Rothschild; D Mandal; T Coons; J Slusser; J Lee; C Gaba; E Kupert; A Perez; X Zhou; D Zeng; Q Liu; Q Zhang; D Seminara; J Minna; M W Anderson
Journal:  Am J Hum Genet       Date:  2004-07-21       Impact factor: 11.025

4.  Patterns of CTCF and ZFHX3 Mutation and Associated Outcomes in Endometrial Cancer.

Authors:  Christopher J Walker; Mario A Miranda; Matthew J O'Hern; Joseph P McElroy; Kevin R Coombes; Ralf Bundschuh; David E Cohn; David G Mutch; Paul J Goodfellow
Journal:  J Natl Cancer Inst       Date:  2015-09-01       Impact factor: 13.506

5.  WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome.

Authors:  María I Nunez; Daniel G Rosen; John H Ludes-Meyers; Martín C Abba; Hyunsuk Kil; Robert Page; Andres J P Klein-Szanto; Andrew K Godwin; Jinsong Liu; Gordon B Mills; C Marcelo Aldaz
Journal:  BMC Cancer       Date:  2005-06-27       Impact factor: 4.430

6.  Imprinting methylation errors in ART.

Authors:  Hitoshi Hiura; Hiroaki Okae; Hatsune Chiba; Naoko Miyauchi; Fumi Sato; Akiko Sato; Takahiro Arima
Journal:  Reprod Med Biol       Date:  2014-06-19

7.  APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer.

Authors:  Rachel Brough; Ilirjana Bajrami; Radost Vatcheva; Rachael Natrajan; Jorge S Reis-Filho; Christopher J Lord; Alan Ashworth
Journal:  EMBO J       Date:  2012-01-31       Impact factor: 11.598

8.  Aberrant CBFA2T3B gene promoter methylation in breast tumors.

Authors:  Anthony J Bais; Alison E Gardner; Olivia L D McKenzie; David F Callen; Grant R Sutherland; Gabriel Kremmidiotis
Journal:  Mol Cancer       Date:  2004-08-10       Impact factor: 27.401

Review 9.  YAP/TAZ Activation as a Target for Treating Metastatic Cancer.

Authors:  Janine S A Warren; Yuxuan Xiao; John M Lamar
Journal:  Cancers (Basel)       Date:  2018-04-10       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.